Here are the 8-K filings from Scribe Therapeutics Inc. (SCTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow SCTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCTX filings page.
Scribe Therapeutics, Inc. (SCTX) reported second quarter 2026 results and highlighted major strategic milestones, including initiation of a first-in-human Phase 1 trial of lead LDL-C lowering candidate STX-1150 and completion of an upsized IPO plus a concurrent private placement to Sanofi.
Collaboration revenue for the quarter was $1.9 million, down from $4.9 million a year earlier, while research and development expenses fell to $8.8 million from $13.9 million. Net loss narrowed to $6.5 million, or $2.62 per share, compared with a $9.9 million loss, or $4.08 per share, in the prior-year period. Cash, cash equivalents and marketable securities were $43.0 million as of June 30, 2026.
The company raised approximately $155.5 million in aggregate gross proceeds from its July 2026 IPO and the Sanofi private placement and expects that, together with existing cash and investments, this will fund operations into the first half of 2029. Scribe also secured more than $25 million in non-dilutive grants from CIRM to advance cardiometabolic programs STX-1200 and STX-1400 toward potential clinical entry as early as 2027.
Scribe Therapeutics Inc. reported that its Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws became effective on July 27, 2026 in connection with the closing of its initial public offering of common stock.
The board of directors and stockholders had previously approved these governance documents to become effective immediately prior to the offering’s closing. Key terms of the charter and bylaws are described in the “Description of Capital Stock” section of the final prospectus dated July 23, 2026, and the full documents are filed as Exhibits 3.1 and 3.2.